Outcomes of children with favorable histology wilms tumor and peritoneal implants treated in National Wilms Tumor Studies-4 and -5
- PMID: 20457352
- PMCID: PMC2868597
- DOI: 10.1016/j.ijrobp.2009.04.081
Outcomes of children with favorable histology wilms tumor and peritoneal implants treated in National Wilms Tumor Studies-4 and -5
Abstract
Purpose: There are no published reports on the optimal management and survival rates of children with Wilms tumor (WT) and peritoneal implants (PIs).
Methods and materials: Among favorable histology WT patients enrolled in the National Wilms Tumor Study (NWTS)-4 and NWTS-5, 57 children had PIs at the time of nephrectomy. The median age was 3 years 5 months (range, 3 months to 14 years). The majority of children (42 of 57 [74%)] had Stage III tumors; 15 had Stage IV disease. All patients received multimodality therapy. Of 56 children who underwent primary surgery, 48 (84%) had gross total resection of all tumors. All patients received 3-drug chemotherapy with vincristine, dactinomycin, and doxorubicin. Whole-abdomen radiotherapy (RT) was used in 47 patients (82%), and in 50 patients (88%) the RT dose was 10.5 Gy.
Results: After a median follow-up of 7.5 years, the overall abdominal and systemic tumor control rates were 97% and 93%, respectively. A comparative analysis between children with PIs and those without PIs showed no significant differences in the clinical characteristics between the two groups. The 5-year event-free survival rates with and without PIs were 90% (95% confidence interval, 78-96%) and 83% (95% confidence interval, 81-85%) respectively (p = 0.20).
Conclusions: Multimodality therapy with surgery, whole-abdomen RT, and three-drug chemotherapy delivered according to the NWTS-4 and -5 protocols resulted in excellent abdominal and systemic tumor control rates. All children should be monitored in long-term surveillance programs for the early detection and management of therapy-related toxicities.
Copyright 2010 Elsevier Inc. All rights reserved.
Conflict of interest statement
The authors have no conflict of interest to disclose.
Similar articles
-
Outcomes of patients with revised stage I clear cell sarcoma of kidney treated in National Wilms Tumor Studies 1-5.Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):428-31. doi: 10.1016/j.ijrobp.2012.04.023. Epub 2012 Jun 1. Int J Radiat Oncol Biol Phys. 2013. PMID: 22658515
-
Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.J Clin Oncol. 2018 Jan 20;36(3):254-261. doi: 10.1200/JCO.2017.73.7999. Epub 2017 Dec 6. J Clin Oncol. 2018. PMID: 29211618 Free PMC article.
-
Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):348-54. doi: 10.1016/j.ijrobp.2010.09.022. Epub 2010 Nov 13. Int J Radiat Oncol Biol Phys. 2012. PMID: 21075548
-
Treatment of Wilms' tumour. Current recommendations.Drugs. 1991 Nov;42(5):766-80. doi: 10.2165/00003495-199142050-00004. Drugs. 1991. PMID: 1723373 Review.
-
Wilms' tumor management.Curr Opin Urol. 2005 Jul;15(4):273-6. doi: 10.1097/01.mou.0000172403.69890.eb. Curr Opin Urol. 2005. PMID: 15928519 Review.
Cited by
-
Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients.Adv Radiat Oncol. 2020 Sep 23;5(6):1267-1273. doi: 10.1016/j.adro.2020.09.004. eCollection 2020 Nov-Dec. Adv Radiat Oncol. 2020. PMID: 33305087 Free PMC article.
-
Updated favourable-histology Wilms tumour risk stratification: rationale for future Children's Oncology Group clinical trials.Nat Rev Urol. 2025 Jun 20. doi: 10.1038/s41585-025-01055-1. Online ahead of print. Nat Rev Urol. 2025. PMID: 40542227 Review.
-
Wilms tumour.Nat Rev Dis Primers. 2021 Oct 14;7(1):75. doi: 10.1038/s41572-021-00308-8. Nat Rev Dis Primers. 2021. PMID: 34650095 Review.
References
-
- D'Angio GJ, Evans AE, Breslow NE, et al. The treatment of Wilms' tumor: results of the National Wilms' Tumor Study. Cancer. 1976;38:633–646. - PubMed
-
- D'Angio GJ, Evans AE, Breslow NE, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer. 1981;47:2302–2311. - PubMed
-
- D'Angio GJ, Breslow N, Beckwith JB, et al. The treatment of Wilms' tumor: results of the Third National Wilms' Tumor Study. Cancer. 1989;64:349–360. - PubMed
-
- Green DM, Breslow NE, Beckwith JB, et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol. 1998;16:237–245. - PubMed
-
- Grundy Paul, Dome Jeffrey, Kalapurakal John A, Perlman Elizabeth, Ritchey Michael. Renal Tumors. In: Carroll William L, Finlay Jonathan L., editors. Cancer in Children. Jones and Bartlett; 2008. in press.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical